Amyloid testing

[neglect]

Hey, no-one started a thread on the biggest story in the last 5 years in neurology: the failure of bapi (Bapineuzumab)!

I'd also say that this heralds the end of of amyloid imaging. With the failure of bapi, there is no reason to find out if they have an amyloid proteinopathy or not. The bapi trials rendered all AD biomarkers useless - if not related in some way with a clinical trial.

---

Members don't see this ad.

 

[typhoonegator]

For those of us who still do research on the topic, Pittsburgh A still has a lot of potential to tease apart the systems biology of amyloid angiopathy and related disorders like AD.

It's easy to get frustrated with setbacks like this, but bapineuzumab was an audacious effort. I agree that for now, clinical testing for AD endophenotypes continues to have limited utility, but we'll keep plugging away at it. Clinical trials aren't the only study designs that benefit from these measurements.